Third Rock Ventures
Third Rock Ventures is an independent life sciences venture firm founded in 2007 that creates and funds biotechnology, medical device and diagnostics companies through its Discover, Launch, Build, Transform model, serving institutional limited partners, scientific founders and portfolio companies.
- Company typePrivate
- Founded2007
- HeadquartersBoston, United States
- Headcount101–250
- GTM typeB2B
- OfferingServices
What Third Rock Ventures does
Third Rock Ventures is an independent, Boston-headquartered venture capital firm founded in 2007 by Mark Levin, Robert Tepper and Kevin Starr, former Millennium Pharmaceuticals executives. It invests in and creates life science companies rather than only funding startups, and serves three constituencies: institutional limited partners that commit capital to dedicated life sciences funds, scientific founders who work with the firm to originate companies, and the resulting portfolio of biotechnology, medical device and diagnostics companies. The firm operates offices in Boston and San Francisco, and its website lists 62 named team members spanning partners, venture partners, advisory partners, entrepreneurs-in-residence, domain experts, principals, associates, fellows, finance, recruiting and operations.
Its core offering is a four-stage company creation process: Discover identifies emerging fields of science and medicine and develops a company concept with scientific founders and expert advisors; Launch provides the financial, technical and human resources plus interim leadership and culture; Build installs experienced management teams, board seats and partnerships; Transform brings products to patients. The firm reports more than 70 companies created and 26 products launched by portfolio companies over 18 years, including Otarmeni, INLEXZO, Aqvesme and the Jewel Patch wearable cardioverter defibrillator. An internal Platform Technologies function develops and deploys shared wet lab, data science, informatics and R&D management systems across portfolio companies and seed projects, while portfolio companies are supported with executive search, recruiting and board-level business development.
Economically the firm operates as a classic venture manager: it earns recurring management fees on committed capital in dedicated life sciences funds — Fund IV ($616 million, 2016), Fund V ($770 million, 2019) and Fund VI ($1.1 billion, 2022) — plus carried interest on realized gains, and returns equity stakes through exits, IPOs and follow-on sales, including Eli Lilly's $2.88 billion acquisition of Merida Biosciences, UCB's agreement to acquire Candid Therapeutics for up to $2.2 billion, and Lisata Therapeutics' acquisition of Marea Therapeutics alongside a $225 million concurrent private placement in which funds may participate. Distribution is relationship-led rather than product-led: the Partner/Chief Operating Officer leads institutional fundraising and LP relationship management, deal flow is sourced from a network of scientific founders and expert advisors, and value creation is pursued through portfolio-company partnerships with large-cap biotech and pharmaceutical companies. Fee, carry and commitment terms are not publicly disclosed; they are communicated directly to limited partners, and the firm publishes no product or service pricing.
Third Rock Ventures firmographics
Firmographics- Name
- Third Rock Ventures
- Legal name
- Third Rock Ventures
- Website
- https://thirdrockventures.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Third Rock Ventures is an independent life sciences venture firm founded in 2007 that creates and funds biotechnology, medical device and diagnostics companies through its Discover, Launch, Build, Transform model, serving institutional limited partners, scientific founders and portfolio companies.
- Ownership category
- akta.pro rank
Third Rock Ventures industry classification
Industry- Product category
- Venture Capital / Life Sciences Investment Management
- NAICS
- Other Investment Pools and Funds (5259), Funds, Trusts, and Other Financial Vehicles (525), Other Financial Vehicles (525990)
- SIC
- Investment Advice (6282), Services-Management Consulting Services (8742)
- akta.pro industry
- Healthcare & Life Sciences Growth EquityLate-Stage Venture Capital (Series C+)
Keywords
Where Third Rock Ventures is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Third Rock Ventures business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D
Revenue model
- Fund management fees and carried interest: The firm manages dedicated life sciences venture funds (Fund IV $616 million in 2016, Fund V $770 million in 2019, Fund VI $1.1 billion in 2022), earning recurring management fees on committed capital plus carried interest on realized gains; the COO/Partner leads fundraising and manages limited partner relationships, and a dedicated finance and fund accounting team (fund reporting, tax, management company accounting) supports it.
- Returns from equity stakes in portfolio companies: Third Rock's funds hold equity in the companies they found and build, so returns are realized through exits — recent examples include Lilly's $2.88 billion acquisition of Merida Biosciences and UCB's up-to-$2.2 billion acquisition of Candid Therapeutics — plus IPO and follow-on liquidity (e.g., Maze Therapeutics IPO and a $150 million registered offering).
- Financing participation in concurrent private placements: Third Rock-backed companies raise large private placements alongside strategic transactions (e.g., the $225 million concurrent private placement by Lisata Therapeutics on the acquisition of Marea Therapeutics), allowing funds and co-investors to participate in financing events.
Go-to-market motion3 records
Distribution channels2 records
Marketing channels6 records
Third Rock Ventures product offering
Product offeringCore offering
Third Rock Ventures is a life sciences venture capital firm that creates biotechnology companies from scratch rather than only funding existing startups. It identifies emerging scientific fields with founders and advisors (Discover), funds and staffs the new company with financial, technical and human resources while its partners serve in interim leadership roles (Launch), installs experienced management teams and continues as board members and domain experts (Build), and drives partnerships, value-creating transactions and products reaching patients (Transform). Revenue comes from management fees and carried interest on its dedicated life sciences venture funds (Fund IV $616M in 2016, Fund V $770M in 2019, Fund VI $1.1B in 2022) plus returns on equity stakes in portfolio companies and participation in concurrent private placements.
Product overview
Third Rock Ventures offers a single, unified company-creation service for healthcare/life-sciences ventures rather than a software platform with plug-in modules: its core offering is the "Company Creation Strategy," delivered through four sequential process modules — Discover (identifying and refining a company concept with scientific founders and advisors), Launch (funding and staffing the new company with Third Rock partners in interim leadership roles), Build (installing experienced management teams, serving as board members, and driving partnerships and value-creating transactions), and Transform (bringing products to patients, with 26 portfolio-company products launched to date). Alongside these modules, the firm operates the "Beyond Great" peer learning community and a portfolio of companies it created, including Syremis Therapeutics (mental health medicines), Azalea Therapeutics (in vivo precision genome engineering for cancer immunotherapy), Merida Biosciences (precision immunology for antibody-driven autoimmune and allergic disease), and Element Science (FDA-approved Jewel® Patch wearable cardioverter defibrillator).
Differentiator
Problem solved
Functional benefit
Brands
- Beyond Great: Beyond Great is Third Rock's learning community for leaders across its portfolio, offering peer-to-peer networking plus tools and resources for building successful, sustainable companies.
Products and services
- Company Creation Strategy Third Rock's founding methodology for creating healthcare and life sciences companies from scratch, built on a patient-first mission and executed in four sequential stages: Discover, Launch, Build and Transform. The firm states it has created more than 70 companies with 26 launched products over 18 years of operation. It is delivered to scientific founders and investors as capital plus scientific, operational and board-level support.
- Discover Collaborative, iterative search for emerging fields of science and medicine where a company concept can be developed with leading scientific founders and expert advisors, producing a clear vision and strategy with the patient front and center. Used by scientific founders and advisors to shape a company concept before capital is committed.
- Launch Funding and staffing a newly conceived company with the financial, technical and human resources needed to reach critical growth milestones, with Third Rock partners serving in interim leadership roles and establishing company culture.
- Build Transitioning out of interim roles to establish experienced management teams, serving as board members and domain experts, cultivating partnerships, and driving value-creating transactions across the portfolio.
- Transform The stage in which portfolio companies bring products to patients; Third Rock reports that its portfolio companies have launched 26 products to date.
- Beyond Great Peer-to-peer learning community available to portfolio company leaders, providing networking and tools and resources focused on shared elements of building successful and sustainable companies.
- Syremis Therapeutics Third Rock-created biotechnology company developing novel medicines for mental health conditions, launched in December 2025 with a $165 million Series A financing.
- Azalea Therapeutics Third Rock-created company enabling precision genome engineering directly inside the body, with an initial focus on creating cancer immunotherapies in vivo; launched in November 2025 with $82 million in financing.
- Merida Biosciences Third Rock-created company advancing a precision immunology approach for antibody-driven diseases that selectively and durably eliminates their pathogenic drivers, enabled by advances in protein engineering and immunology, targeting inadequately treated autoimmune and allergic conditions; launched with $121 million in April 2025 and acquired by Eli Lilly for $2.88 billion.
- Jewel® Patch Wearable Cardioverter Defibrillator (Element Science) FDA-approved wearable cardioverter defibrillator patch developed by Third Rock portfolio company Element Science, designed to protect individuals at temporary risk of sudden cardiac arrest without interrupting their lives; the first patch-based wearable defibrillator.
Quantifiable outcome
- Over 70 companies created with 18 years of company-creation experience
- +6 more outcomes
Companies that use Third Rock Ventures
Customer profileNamed customers9 records
Segments3 records
Ideal customer profiles3 records
Third Rock Ventures technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Third Rock Ventures partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered minor — talent pipeline initiative for diverse candidates, core — oncology-focused co-investment and innovation collaboration and flagship — industry-leading global strategic collaboration.
- Project Onrampminor — talent pipeline initiative for diverse candidatesThird Rock Ventures became the founding partner for Project Onramp's national expansion, announced in February 2023. The initiative supports the pipeline of diverse, untapped talent entering the biotech industry, complementing the firm's recruiting and talent strategy for portfolio companies.
- American Cancer Society Impact Venture Capital Arm (BrightEdge)core — oncology-focused co-investment and innovation collaborationThird Rock Ventures and the American Cancer Society's Impact Venture Capital arm announced a collaboration to drive innovation in oncology. The alliance links Third Rock's company creation platform with the ACS Impact VC arm's focus on cancer innovation, giving founders access to capital plus company creation support in oncology.
- Celgeneflagship — industry-leading global strategic collaborationCary Pfeffer, as head of Third Rock's partner development, played an instrumental role in an industry-leading global strategic collaboration between Agios (a Third Rock portfolio company) and Celgene in the field of cancer metabolism. The relationship illustrates the firm's ability to bring major biotech and pharmaceutical companies into collaborations with its portfolio.
Scale indicators12 records
Recent moves10 records
Expansion highlights6 records
Third Rock Ventures competitors and assessment
Company assessmentDirect peers
- Flagship Pioneering: Boston-based life sciences company-creation firm that originates, builds and scales new companies from scientific hypotheses alongside venture investment. It matches Third Rock on operating model, customer base of scientific founders, target life sciences stages and reliance on strategic exits.
- Foresite Capital: San Francisco venture firm investing at all stages of life sciences with a dedicated company-creation practice that builds companies with founders and scientific advisors. Comparable to Third Rock in biotech focus, founder-centric origination and mixed fund/creation economics.
- Arch Venture Partners: Life sciences investor operating dedicated company-creation funds alongside traditional venture funds, originating and building companies from novel scientific platforms. It competes with Third Rock for founder relationships and for multi-hundred-million-dollar biotech financings.
- Versant Ventures: Cambridge, Massachusetts investor focused exclusively on creating and funding biotechnology companies from inception, with an internal network of operating advisors and specialized funds. Its geography, biotech-only mandate and company-creation model closely parallel Third Rock's.
- 5AM Ventures: Early-stage life sciences venture firm that also builds companies with scientific founders, combining funds with hands-on operating and formation support. Comparable to Third Rock in healthcare focus, stage and company-creation-led value proposition.
- Lux Capital: Investor in emerging science and deep technology that routinely forms new companies with scientific founders and provides operating leadership. Overlaps with Third Rock's Discover-to-Transform creation process and its scientific talent bench.
- Atlas Venture: Long-established healthcare and life sciences venture firm based in Boston and Cambridge that both funds and builds companies with founders and executives. Comparable on life sciences specialization, company-creation orientation, LP base and strategic-exit driven returns.
Broad incumbents
- Deerfield Management: Specialist healthcare investment firm with dedicated company-creation and growth vehicles alongside traditional venture funds, competing for the same therapeutic franchises and founder relationships. It is larger and more broadly diversified across healthcare than Third Rock's biotech-only model.
- RA Capital Management: Large specialist healthcare venture investor with deep clinical-stage portfolios and a strong follow-on funding model. It overlaps on investors, therapeutic focus and financing stages but does not compete for founder-driven company creation in the same way as Third Rock.
- GV: Large global venture platform with one of the industry's largest life sciences practices, providing capital and partnership support to biotech companies. It overlaps with Third Rock on biotech funding and strategic collaborations, but its portfolio spans many technology sectors rather than company-creation-only life sciences.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Third Rock Ventures social profiles
Digital presenceThird Rock Ventures financial estimates
Financial estimateRevenue estimate
Valuation estimate
Third Rock Ventures leadership team
Management profileNumber of profiles
Profiles27 records
Third Rock Ventures funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Third Rock Ventures M&A and investment
M&A and investmentM&A
Investments160 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Third Rock Ventures
What does Third Rock Ventures do?
Third Rock Ventures is a life sciences venture capital firm that creates biotechnology companies from scratch rather than only funding existing startups. It identifies emerging scientific fields with founders and advisors (Discover), funds and staffs the new company with financial, technical and human resources while its partners serve in interim leadership roles (Launch), installs experienced management teams and continues as board members and domain experts (Build), and drives partnerships, value-creating transactions and products reaching patients (Transform). Revenue comes from management fees and carried interest on its dedicated life sciences venture funds (Fund IV $616M in 2016, Fund V $770M in 2019, Fund VI $1.1B in 2022) plus returns on equity stakes in portfolio companies and participation in concurrent private placements.
Is Third Rock Ventures a public or private company?
Third Rock Ventures is a private company. It is classified as venture growth investor backed and is currently operating.
When was Third Rock Ventures founded?
Third Rock Ventures was founded in 2007. It employs 101 to 250 people.
Where is Third Rock Ventures based?
Third Rock Ventures is headquartered in Boston, United States, in the North America region.
How does Third Rock Ventures make money?
Three revenue lines are on record. Fund management fees and carried interest is the primary driver. The others are returns from equity stakes in portfolio companies and financing participation in concurrent private placements.
Who are Third Rock Ventures's main competitors?
Direct peers on record are Flagship Pioneering, Foresite Capital, Arch Venture Partners, Versant Ventures, 5AM Ventures, Lux Capital and Atlas Venture. Broad incumbents are Deerfield Management, RA Capital Management and GV.
Does Third Rock Ventures have an API?
No public API is recorded for Third Rock Ventures.
What industry is Third Rock Ventures in?
Third Rock Ventures's product category is Venture Capital / Life Sciences Investment Management. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity, with a secondary code of FSANAAAC, Late-Stage Venture Capital (Series C+). Its NAICS code is 5259 and its SIC code is 6282.